Bcl‐XL plays a particularly important role in shifting venetoclax sensitivity versus resistance of CLL cells in the context of CD40 stimulation [12, 15, 22]. This evidence concerns the gene BCL2L1 and B-cell chronic lymphocytic leukemia.